BBOT — BridgeBio Oncology Therapeutics Inc. stock price, charts and financials

QT59BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
9.36
+0.03+0.32%
OverviewShort InterestFilings
BBOTQT59BridgeBio Oncology Therapeutics Inc.·NASDAQ
9.36+0.32%
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.24%$15.49MESO+4.92%$16.73ZBIO-0.80%$32.17GHRS-1.85%$29.71TSHA-0.67%$6.52STOK-1.01%$32.38ABCL+32.25%$9.16VRDN-1.42%$23.26
Snapshot
Index-P/E-EPS (ttm)-Insider Own32.01%Shs Outstand80.11MPerf Week15.33%
Market Cap747.40MForward P/E-EPS next Y-2.18Insider Trans0.00%Shs Float452.99KPerf Month2.64%
Enterprise Value697.39MPEG0.02EPS next Q-Inst Own-Short Float7.10%Perf Quarter18.70%
Income-396.35MP/S0.00EPS this Y-Inst Trans-Short Ratio12.29Perf Half Y-8.08%
Sales0.00P/B0.78EPS next Y4.82%ROA-36.90%Short Interest5.69MPerf YTD-25.48%
Book/sh-P/C-EPS next 5Y-ROE-61.49%52W High14.92 -37.26%Perf Year-
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-45.04%52W Low7.02 33.29%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.76% 6.44%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-11479.35%Oper. Margin0.00%ATR (14)0.55Perf 10Y-
Dividend Ex-Date-Quick Ratio6.16Sales Y/Y TTM-Profit Margin0.00%RSI (14)61.19Recom2.00
Dividend Gr. 3/5Y-Current Ratio6.16EPS Q/Q99.08%SMA208.14%Beta1.34Target Price23.00
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA5013.35%Rel Volume0.53Prev Close9.33
Employees92LT Debt/Eq0.00EarningsAug 11SMA200-7.33%Avg Volume412.40KPrice9.36
IPO DateAug 12, 2025Option/ShortNo / YesEPS/Sales Surpr.6.24% -Net Debt/EBITDA0.30Volume219,409Change0.32%
Analyst Ratings
DateActionAnalystRatingTarget
May-11-26InitiatedCanaccordBuy$23
Feb-10-26InitiatedStifelBuy$23
Jan-09-26InitiatedRaymond JamesOutperform$24
Jan-08-26ReiteratedMorgan Stanley$20 → $18
Dec-05-25InitiatedMorgan StanleyOverweight$20
Sep-17-25InitiatedLeerinkOutperform$25
Sep-15-25InitiatedH.CBuy$27
Sep-04-25InitiatedOppenheimerOutperform$23
Aug-15-25InitiatedPiper SandlerOverweight$21
Latest News
Company

BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
Total Revenue
000——
Cost of Goods Sold Incl. D&A
000——
Gross Profit
000——
Selling, General and Administrative Excl. Other2588——
Research and Development1217356——
Other Operating Expense001——
Operating Income-146-81-65——
Interest Expense
000——
Unusual Expense
—————
Non-Operating Income (Expense)1270——
Net Income Before Taxes-134-74-65——
Income Taxes
000——
Consolidated Net Income-134-74-65——
Net Income From Continuing Operations-1348-65——
Net Income-134-74-65——
EPS (Recurring)-4.300.46-3.16——
EPS (Basic, Before Extraordinaries)-4.300.46-3.16——
EPS (Diluted)-4.300.46-3.16——
EBITDA-145-81-65——
Other After Tax Adjustments
—————
Stock Option Compensation Expense
—————
Price To Earnings Ratio—22.83———
Price To Sales Ratio
—————
Gross Margin
—————
Operating Margin
—————
Net Margin
—————
Shares Outstanding311720——
Market Capitalization388179———
Operating Lease Expense
—————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$14.72$12.57$10.43$8.28$6.13● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Chen Bihuadirector, 10 percent owner:Aug 11 '25Option Exercise0.004,172,1264174,681,126Aug 13
Holman Albert A IIIother: Former DirectorAug 11 '25Option Exercise0.0030,000030,000Aug 11
McKenna Mark C.other: Former DirectorAug 11 '25Option Exercise0.0030,000030,000Aug 11
Schmid John P.other: Former DirectorAug 11 '25Option Exercise0.0030,000030,000Aug 11
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.